asundexian

News

Anthos hails win over Xarelto with novel anticoagulant

Anthos Therapeutics says a phase 2b trial of its factor XI inhibitor anticoagulant abelacimab has been stopped early due to an “overwhelming” reduction in bleeding complic

News

ESC22: Despite trial misses, Bayer preps phase 3 for asundex...

Bayer is pressing ahead with a phase 3 trial of its oral Factor XIa inhibitor asundexian, a new anticoagulant, despite missing efficacy targets in two mid-stage studies.

News

FDA fast tracks Bayer's oral anticoagulant asundexian

The FDA has granted fast-track status to Bayer's oral Factor Xia inhibitor asundexian, which is in phase 2 testing as an anticoagulant that could offer safety advantages over current drugs.

Anthos hails win over Xarelto with novel anticoagulant

ESC22: Despite trial misses, Bayer preps phase 3 for asundex...

FDA fast tracks Bayer's oral anticoagulant asundexian

Tenax trounced by phase 3 heart failure readout

Discover a new era of healthcare panel engagement: Grounded ...

Editor's Picks